- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02011178
Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine (PROMISE)
Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine; a Prospectivee, Randomized, Multicenter Study
Background: Diabetic kidney disease (DKD) is chronic and often progresses to kidney failure,heart disease and premature death. Unfortunately, the best medical therapies available for DKD today are ultimately unable to prevent its progression, especially in obese patients.Surgical rerouting of food within the gut with a gastric bypass operation (RYGB), improves diabetes and some of its complications.
The investigators propose to investigate whether RYGB in combination with best medical therapy in patients with DKD and obesity prevent further deterioration of kidney function over a 3 years follow up period.
Study design: This is an international collaboration with leading centres in Sweden and Switzerland in which100 obese type 2 diabetic patients with established DKD will volunteer to be randomly assigned to receive best medical therapy with RYGB or best medical therapy without surgery. Participants will be 18-65 years with type 2 diabetes and impaired kidney function. Yearly measurements of kidney function will then be done over a period of 3 years as a primary outcome to determine whether differences in DKD can be detectable. The study will also examine and compare a) safety of the interventions, b) the health economic impact on direct healthcare costs and Quality of Life in patients as well as c) the value of a new marker of DKD in determining which patients are most likely to benefit from surgery.
Overall the study will strengthen the evidence base guiding clinical decisions about the usefulness of RYGB as an add on therapy to best medical therapy in stopping progressive DKD in patients with obesity and diabetes.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 116 28
- Ersta Hospital
-
-
-
-
-
Basel, Switzerland, 4058
- St:Claraspital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• BMI 28 - 35 kg/m2
- Age: 18-65 years, with T2DM
- Estimated glomerular filtration rate (eGFR; by MDRD) between 30 and 60mL/min/1.73m2
- Urine albumin creatinine ratio (ACR) of at least 30mg/g (microalbuminuria) in first void urine on two separate days.
Exclusion Criteria:
• Type 1 diabetes or a positive GAD antibody test
- Known renal artery stenosis
- Renal impairment for reasons unrelated to diabetes
- Suspicion of glomerulonephritis as determined by urine sediment (>10 erythrocytes/visual field)
- Post-renal obstruction diagnosed by ultrasound
- Severe retinopathy (defined as high-risk proliferative diabetic retinopathy and severe visual loss according to the "Early Treatment Diabetic Retinopathy Study Severity Scale")
- Severe DKD (CKD 4 or 5, requirement of renal replacement therapy such as dialysis or kidney transplantation)
- Severe neuropathy (peripheral neuropathy stage 3)
- Unacceptably high risk for general anesthesia
- Prior extensive intra-abdominal surgery making laparoscopy complicated
- Myocardial infarction, cerebrovascular accident, transient ischemic attack, coronary-artery bypass grafting or percutaneous transluminal coronary angioplasty within the previous 6 months
- Cardiac failure (NYHA stage > 2)
- Inability to stop smoking prior to inclusion
- Pregnancy or breast feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Optimal medical treatment and surgery
In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol in combination with RYGB surgery.
|
|
Other: Optimal medical treatment
In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glomerular filtration rate
Time Frame: Three years after intervention
|
Renal function measurement by Iohexol clearance
|
Three years after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microvascular kidney damage
Time Frame: 3 years after intervention
|
Microvascular kidney damage measured by Albumin/Creatinine Ratio
|
3 years after intervention
|
Glycaemic control
Time Frame: 3 years after intervention
|
HbA1c and fasting plasma glucose measurements .
Five day continuous glucose monitoring
|
3 years after intervention
|
peripheral nervous system function
Time Frame: 3 years after intervention
|
Michigan Neuropathy Screening Instrument (MNSI) score, which includes two separate assessments: a lower extremity examination that includes inspection of the feet to identify deformities, dry skin, calluses, infection, fissure, or ulcers, and assessment of vibratory sensation and ankle reflexes
|
3 years after intervention
|
autonomic nervous system function
Time Frame: 3 years after intervention
|
Autonomic neuropathy will be assessed with the RR intervals on ECG during deep breathing test
|
3 years after intervention
|
diabetic eyes complications
Time Frame: 3 years after intervention
|
Using retinal photos and using the International Clinical Diabetic Retinopathy Disease Severity Scale
|
3 years after intervention
|
blood preassure
Time Frame: 3 years after intervention
|
Blood pressure will be recorded with calibrated and validated electronic blood pressure equipment and appropriate sized cuff.
Patients will sit in a chair in a quiet room for 5 minutes.
|
3 years after intervention
|
Lipids
Time Frame: 3 years after intervention
|
Total cholesterol, low density lipoprotein, high density lipoprotein cholesterol and triglycerides will be measured
|
3 years after intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
health economics
Time Frame: from intervention and three years forward
|
Direct healthcare resource consumption.
Costs to Governments or Insurance companies plus private expenditure on health.
Costs will include primary and secondary surgery, medication, laboratory tests, health provider reimbursement, private prescription charges and co-payments for medications
|
from intervention and three years forward
|
Quality of life score
Time Frame: three years after intervention
|
Quality of life will be measured by the general health 36-item Health Survey (SF-36)
|
three years after intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Thorell Anders, Professor, Karolinska Institutet
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013/1530-31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Kidney Disease
-
University of UtahNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHemodialysis | Kidney Disease, Chronic | Kidney Failure | Dialysis | Diabetic | End-stage Kidney Disease | Kidney Dysfunction | Non-diabeticUnited States
-
Eli Lilly and CompanyTerminatedDiabetic Nephropathy | Diabetic Kidney Disease | Diabetic GlomerulosclerosisIsrael, Hungary, United States, Australia, France, Czechia, Puerto Rico
-
Chinese PLA General HospitalBeijing Friendship Hospital; Guang'anmen Hospital of China Academy of Chinese... and other collaboratorsRecruitingDiabetic Kidney DiseaseChina
-
Omar Tarek ElfarargiNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...Not yet recruitingEstablishment and Clinical Validation of a New Technique for Early Diagnosis of Diabetic NephropathyDiabetes Mellitus | Diabetic Kidney Disease | Biomarkers | Early Diagnosis
-
Fayoum UniversityCairo UniversityNot yet recruitingSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Mayo ClinicRegenerative Medicine MinnesotaTerminatedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Kidney Disease | Diabetic Nephropathies | Chronic Kidney Disease | Kidney Failure | Diabetic Nephropathy Type 2 | Kidney InsufficiencyUnited States
-
CSL BehringCompletedDiabetic Kidney Disease (DKD)United States, Australia, New Zealand, Puerto Rico, Canada, Israel
-
Universidad Estatal de MilagroSecretaría de Ciencia, Tecnología e Innovación (Senescyt); PROMETEOUnknownKidney Diseases | Diabetes Mellitus | Diabetic Nephropathy | Diabetic Kidney Disease | Chronic Kidney DiseaseEcuador
-
University of California, San DiegoRecruiting
Clinical Trials on Optimal medical treatment and surgery
-
Uptake Medical Technology, Inc.MedPass InternationalNot yet recruiting
-
Aeris TherapeuticsTerminatedPulmonary EmphysemaUnited States, Spain, France, Israel, Netherlands, Greece, Italy
-
Uptake Medical CorpCompletedEmphysemaAustralia, Ireland, Germany, Austria, New Zealand, United Kingdom
-
Helios Health Institute GmbHHeart Center Leipzig - University Hospital; IHF GmbH - Institut für HerzinfarktforschungActive, not recruitingAcute Myocardial Infarction | Cardiogenic ShockGermany
-
Danish Study GroupDanish Heart FoundationCompletedHeart Failure | Dilated Cardiomyopathy | Reduced LVEFDenmark
-
Danish Study GroupDanish Heart FoundationCompletedHeart Failure | Dilated Cardiomyopathy | Reduced LVEFDenmark
-
Shanghai Chest HospitalNot yet recruiting
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaCompletedCoronary Artery Disease | Plaque, AtheroscleroticKorea, Republic of, Taiwan, United States, Japan, New Zealand
-
Josep Rodes-CabauActive, not recruitingPatent Foramen Ovale | Cryptogenic Stroke | Older Patients | Medical Treatment | Recurrent StrokeCanada
-
University Hospital, AngersActive, not recruitingChronic Myeloid Leukemia (CML)France